explore -WSS

explore

author：hotspot 2025-09-30 17:46:28 - browse：41

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： In Memoriam: Notable people who died in 2023
Next article： WATCH: Why do our ears pop?

WSS

Congress may force more Covid

As AI regulations shape up, health tech startups beg for clarity

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

Measles policy set amid Florida outbreak alarms vaccine proponents

5 shark bites reported on Long Island as officials deploy surveillance drones

Researchers tackle phage therapy hurdles for wider adoption

explore

explore

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

focus

Continuity nursing helped my family in our darkest PICU moments

Man with guns arrested near Obama home 'attempted to evade' Secret Service: Prosecutors

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Guidelines to prevent youth baseball injuries need more muscle

Abridge raises $150m as clinical notes automation market heats up

Dobbs anniversary: the lost opportunity of abortion as health care

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

How to save PrEP access — and even expand it

MD Anderson's Padmanee Sharma responds to research credit suit

leisure time

Ukraine seeks to reclaim its role as a hub for clinical trials

FDA warns medical device makers about rise in fabricated data

2 million sign

Researchers tackle phage therapy hurdles for wider adoption

China dismisses criticism of top diplomat's comments appearing to push for race

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

entertainment

focus

explore

leisure time